HyTdb

Poloxin-2HT+

HyT-011 | Adamantane | Published 2019.03.08

Basic Information

Poloxin-2
Linker
Adamantane
POIPLK1 — Serine/threonine-protein kinase PLK1(PLK1); PLK2 — Serine/threonine-protein kinase PLK2(PLK2); PLK3 — Serine/threonine-protein kinase PLK3(PLK3)
Degradation Pathway
Published2019.03.08

Remarks

Chemical Identifiers

SMILESC[C@H](CCC12C[C@H]3C[C@H](C[C@@H](C2)C3)C1)C(NCCOCCOCCCCCCN4N=NC(CCC(NCC5=CC=C(C(O/N=C(C=C6C)/C(C)=CC6=O)=O)C(C)=C5)=O)=C4)=O
Molecular FormulaC47H66N6O7
InChIInChI=1S/C47H66N6O7/c1-32(13-14-47-27-37-24-38(28-47)26-39(25-37)29-47)45(56)48-15-18-59-20-19-58-17-8-6-5-7-16-53-31-40(50-52-53)10-12-44(55)49-30-36-9-11-41(33(2)21-36)46(57)60-51-42-22-35(4)43(54)23-34(42)3/h9,11,21-23,31-32,37-39H,5-8,10,12-20,24-30H2,1-4H3,(H,48,56)(H,49,55)/b51-42+/t32-,37-,38+,39-,47?/m1/s1
InChI KeyBQXHVNSZFNOCDQ-STFMFNQTSA-N
IUPAC Name[(E)-(2,5-dimethyl-4-oxocyclohexa-2,5-dien-1-ylidene)amino] 4-[[3-[1-[6-[2-[2-[[(2R)-4-(1-adamantyl)-2-methylbutanoyl]amino]ethoxy]ethoxy]hexyl]triazol-4-yl]propanoylamino]methyl]-2-methylbenzoate
PubChem CID172016054

Basic Properties

TPSAComputing…
RingsComputing…
FSP3Computing…
Heavy Atom CountComputing…

Lipinski RO5

RO5 ViolationComputing…
MWComputing…
ClogPComputing…
HBDComputing…
HBAComputing…
RBComputing…

Hydrophobic Tag Properties

Tag Structure
Tag TypeAdamantane
Tag SMILESC1(CC2C3)CC(C2)CC3C1
Tag ClogP5.022
HydrophobicityHigh(ClopP>5)

Mechanism of Action

POI (Protein of Interest)

POI NameSerine/threonine-protein kinase PLK1(PLK1)
GenePLK1
UniProt IDP53350

Amino Acid Sequence

MSAAVTAGKLARAPADPGKAGVPGVAAPGAPAAAPPAKEIPEVLVDPRSRRRYVRGRFLGKGGFAKCFEISDADTKEVFAGKIVPKSLLLKPHQREKMSMEISIHRSLAHQHVVGFHGFFEDNDFVFVVLELCRRRSLLELHKRRKALTEPEARYYLRQIVLGCQYLHRNRVIHRDLKLGNLFLNEDLEVKIGDFGLATKVEYDGERKKTLCGTPNYIAPEVLSKKGHSFEVDVWSIGCIMYTLLVGKPPFETSCLKETYLRIKKNEYSIPKHINPVAASLIQKMLQTDPTARPTINELLNDEFFTSGYIPARLPITCLTIPPRFSIAPSSLDPSNRKPLTVLNKGLENPLPERPREKEEPVVRETGEVVDCHLSDMLQQLHSVNASKPSERGLVRQEEAEDPACIPIFWVSKWVDYSDKYGLGYQLCDNSVGVLFNDSTRLILYNDGDSLQYIERDGTESYLTVSSHPNSLMKKITLLKYFRNYMSEHLLKAGANITPREGDELARLPYLRTWFRTRSAIILHLSNGSVQINFFQDHTKLILCPLMAAVTYIDEKRDFRTYRLSLLEEYGCCKELASRLRYARTMVDKLLSSRSASNRLKAS

3D Structure (/structures/AF-P53350-F1-model_v6.cif)

Loading /structures/AF-P53350-F1-model_v6.cif …

Function

Serine/threonine-protein kinase that performs several important functions throughout M phase of the cell cycle, including the regulation of centrosome maturation and spindle assembly, the removal of cohesins from chromosome arms, the inactivation of anaphase-promoting complex/cyclosome (APC/C) inhibitors, and the regulation of mitotic exit and cytokinesis. Polo-like kinase proteins act by binding and phosphorylating proteins that are already phosphorylated on a specific motif recognized by the POLO box domains. Phosphorylates BORA, BUB1B/BUBR1, CCNB1, CDC25C, CEP55, ECT2, ERCC6L, FBXO5/EMI1, FOXM1, KIF20A/MKLP2, CENPU, NEDD1, NINL, NPM1, NUDC, PKMYT1/MYT1, KIZ, MRE11, PPP1R12A/MYPT1, POLQ, PRC1, RACGAP1/CYK4, RAD51, RHNO1, SGO1, STAG2/SA2, TEX14, TOPORS, p73/TP73, TPT1, WEE1 and HNRNPU Plays a key role in centrosome functions and the assembly of bipolar spindles by phosphorylating KIZ, NEDD1 and NINL (PubMed:16980960, PubMed:19509060). NEDD1 phosphorylation promotes subsequent targeting of the gamma-tubulin ring complex (gTuRC) to the centrosome, an important step for spindle formation. Phosphorylation of NINL component of the centrosome leads to NINL dissociation from other centrosomal proteins. Involved in mitosis exit and cytokinesis by phosphorylating CEP55, ECT2, KIF20A/MKLP2, CENPU, PRC1 and RACGAP1. Recruited at the central spindle by phosphorylating and docking PRC1 and KIF20A/MKLP2; creates its own docking sites on PRC1 and KIF20A/MKLP2 by mediating phosphorylation of sites subsequently recognized by the POLO box domains. Phosphorylates RACGAP1, thereby creating a docking site for the Rho GTP exchange factor ECT2 that is essential for the cleavage furrow formation. Promotes the central spindle recruitment of ECT2. Plays a central role in G2/M transition of mitotic cell cycle by phosphorylating CCNB1, CDC25C, FOXM1, CENPU, PKMYT1/MYT1, PPP1R12A/MYPT1 and WEE1. Part of a regulatory circuit that promotes the activation of CDK1 by phosphorylating the positive regulator CDC25C and inhibiting the negative regulators WEE1 and PKMYT1/MYT1. Also acts by mediating phosphorylation of cyclin-B1 (CCNB1) on centrosomes in prophase. Phosphorylates FOXM1, a key mitotic transcription regulator, leading to enhance FOXM1 transcriptional activity. Involved in kinetochore functions and sister chromatid cohesion by phosphorylating BUB1B/BUBR1, FBXO5/EMI1 and STAG2/SA2. PLK1 is high on non-attached kinetochores suggesting a role of PLK1 in kinetochore attachment or in spindle assembly checkpoint (SAC) regulation. Required for kinetochore localization of BUB1B. Regulates the dissociation of cohesin from chromosomes by phosphorylating cohesin subunits such as STAG2/SA2 (By similarity). Phosphorylates SGO1: required for spindle pole localization of isoform 3 of SGO1 and plays a role in regulating its centriole cohesion function. Mediates phosphorylation of FBXO5/EMI1, a negative regulator of the APC/C complex during prophase, leading to FBXO5/EMI1 ubiquitination and degradation by the proteasome. Acts as a negative regulator of p53 family members: phosphorylates TOPORS, leading to inhibit the sumoylation of p53/TP53 and simultaneously enhance the ubiquitination and subsequent degradation of p53/TP53. Phosphorylates the transactivation domain of the transcription factor p73/TP73, leading to inhibit p73/TP73-mediated transcriptional activation and pro-apoptotic functions. Phosphorylates BORA, and thereby promotes the degradation of BORA. Contributes to the regulation of AURKA function. Also required for recovery after DNA damage checkpoint and entry into mitosis. Phosphorylates MISP, leading to stabilization of cortical and astral microtubule attachments required for proper spindle positioning. Together with MEIKIN, acts as a regulator of kinetochore function during meiosis I: required both for mono-orientation of kinetochores on sister chromosomes and protection of centromeric cohesin from separase-mediated cleavage (By similarity). Phosphorylates CEP68 and is required for its degradation. Regulates nuclear envelope breakdown during prophase by phosphorylating DCTN1 resulting in its localization in the nuclear envelope. Phosphorylates the heat shock transcription factor HSF1, promoting HSF1 nuclear translocation upon heat shock. Phosphorylates HSF1 also in the early mitotic period; this phosphorylation regulates HSF1 localization to the spindle pole, the recruitment of the SCF(BTRC) ubiquitin ligase complex induicing HSF1 degradation, and hence mitotic progression. Regulates mitotic progression by phosphorylating RIOK2. Through the phosphorylation of DZIP1 regulates the localization during mitosis of the BBSome, a ciliary protein complex involved in cilium biogenesis. Regulates DNA repair during mitosis by mediating phosphorylation of POLQ and RHNO1, thereby promoting POLQ recruitment to DNA damage sites. Phosphorylates ATXN10 which may play a role in the regulation of cytokinesis and may stimulate the proteasome-mediated degradation of ATXN10.

POI NameSerine/threonine-protein kinase PLK2(PLK2)
GenePLK2
UniProt IDQ9NYY3

Amino Acid Sequence

MELLRTITYQPAASTKMCEQALGKGCGADSKKKRPPQPPEESQPPQSQAQVPPAAPHHHHHHSHSGPEISRIIVDPTTGKRYCRGKVLGKGGFAKCYEMTDLTNNKVYAAKIIPHSRVAKPHQREKIDKEIELHRILHHKHVVQFYHYFEDKENIYILLEYCSRRSMAHILKARKVLTEPEVRYYLRQIVSGLKYLHEQEILHRDLKLGNFFINEAMELKVGDFGLAARLEPLEHRRRTICGTPNYLSPEVLNKQGHGCESDIWALGCVMYTMLLGRPPFETTNLKETYRCIREARYTMPSSLLAPAKHLIASMLSKNPEDRPSLDDIIRHDFFLQGFTPDRLSSSCCHTVPDFHLSSPAKNFFKKAAAALFGGKKDKARYIDTHNRVSKEDEDIYKLRHDLKKTSITQQPSKHRTDEELQPPTTTVARSGTPAVENKQQIGDAIRMIVRGTLGSCSSSSECLEDSTMGSVADTVARVLRGCLENMPEADCIPKEQLSTSFQWVTKWVDYSNKYGFGYQLSDHTVGVLFNNGAHMSLLPDKKTVHYYAELGQCSVFPATDAPEQFISQVTVLKYFSHYMEENLMDGGDLPSVTDIRRPRLYLLQWLKSDKALMMLFNDGTFQVNFYHDHTKIIICSQNEEYLLTYINEDRISTTFRLTTLLMSGCSSELKNRMEYALNMLLQRCN

3D Structure (/structures/AF-Q9NYY3-F1-model_v6.cif)

Loading /structures/AF-Q9NYY3-F1-model_v6.cif …

Function

Tumor suppressor serine/threonine-protein kinase involved in synaptic plasticity, centriole duplication and G1/S phase transition. Polo-like kinases act by binding and phosphorylating proteins that are already phosphorylated on a specific motif recognized by the POLO box domains. Phosphorylates CPAP, NPM1, RAPGEF2, RASGRF1, SNCA, SIPA1L1 and SYNGAP1. Plays a key role in synaptic plasticity and memory by regulating the Ras and Rap protein signaling: required for overactivity-dependent spine remodeling by phosphorylating the Ras activator RASGRF1 and the Rap inhibitor SIPA1L1 leading to their degradation by the proteasome. Conversely, phosphorylates the Rap activator RAPGEF2 and the Ras inhibitor SYNGAP1, promoting their activity. Also regulates synaptic plasticity independently of kinase activity, via its interaction with NSF that disrupts the interaction between NSF and the GRIA2 subunit of AMPARs, leading to a rapid rundown of AMPAR-mediated current that occludes long term depression. Required for procentriole formation and centriole duplication by phosphorylating CPAP and NPM1, respectively. Its induction by p53/TP53 suggests that it may participate in the mitotic checkpoint following stress.

POI NameSerine/threonine-protein kinase PLK3(PLK3)
GenePLK3
UniProt IDQ9H4B4

Amino Acid Sequence

MEPAAGFLSPRPFQRAAAAPAPPAGPGPPPSALRGPELEMLAGLPTSDPGRLITDPRSGRTYLKGRLLGKGGFARCYEATDTETGSAYAVKVIPQSRVAKPHQREKILNEIELHRDLQHRHIVRFSHHFEDADNIYIFLELCSRKSLAHIWKARHTLLEPEVRYYLRQILSGLKYLHQRGILHRDLKLGNFFITENMELKVGDFGLAARLEPPEQRKKTICGTPNYVAPEVLLRQGHGPEADVWSLGCVMYTLLCGSPPFETADLKETYRCIKQVHYTLPASLSLPARQLLAAILRASPRDRPSIDQILRHDFFTKGYTPDRLPISSCVTVPDLTPPNPARSLFAKVTKSLFGRKKKSKNHAQERDEVSGLVSGLMRTSVGHQDARPEAPAASGPAPVSLVETAPEDSSPRGTLASSGDGFEEGLTVATVVESALCALRNCIAFMPPAEQNPAPLAQPEPLVWVSKWVDYSNKFGFGYQLSSRRVAVLFNDGTHMALSANRKTVHYNPTSTKHFSFSVGAVPRALQPQLGILRYFASYMEQHLMKGGDLPSVEEVEVPAPPLLLQWVKTDQALLMLFSDGTVQVNFYGDHTKLILSGWEPLLVTFVARNRSACTYLASHLRQLGCSPDLRQRLRYALRLLRDRSPA

3D Structure (/structures/AF-Q9H4B4-F1-model_v6.cif)

Loading /structures/AF-Q9H4B4-F1-model_v6.cif …

Function

Serine/threonine-protein kinase involved in cell cycle regulation, response to stress and Golgi disassembly. Polo-like kinases act by binding and phosphorylating proteins that are already phosphorylated on a specific motif recognized by the POLO box domains. Phosphorylates ATF2, BCL2L1, CDC25A, CDC25C, CHEK2, HIF1A, JUN, p53/TP53, p73/TP73, PTEN, TOP2A and VRK1. Involved in cell cycle regulation: required for entry into S phase and cytokinesis. Phosphorylates BCL2L1, leading to regulate the G2 checkpoint and progression to cytokinesis during mitosis. Plays a key role in response to stress: rapidly activated upon stress stimulation, such as ionizing radiation, reactive oxygen species (ROS), hyperosmotic stress, UV irradiation and hypoxia. Involved in DNA damage response and G1/S transition checkpoint by phosphorylating CDC25A, p53/TP53 and p73/TP73. Phosphorylates p53/TP53 in response to reactive oxygen species (ROS), thereby promoting p53/TP53-mediated apoptosis. Phosphorylates CHEK2 in response to DNA damage, promoting the G2/M transition checkpoint. Phosphorylates the transcription factor p73/TP73 in response to DNA damage, leading to inhibit p73/TP73-mediated transcriptional activation and pro-apoptotic functions. Phosphorylates HIF1A and JUN is response to hypoxia. Phosphorylates ATF2 following hyperosmotic stress in corneal epithelium. Also involved in Golgi disassembly during the cell cycle: part of a MEK1/MAP2K1-dependent pathway that induces Golgi fragmentation during mitosis by mediating phosphorylation of VRK1. May participate in endomitotic cell cycle, a form of mitosis in which both karyokinesis and cytokinesis are interrupted and is a hallmark of megakaryocyte differentiation, via its interaction with CIB1.

Degradation Pathway

Activity Data

TypeDC50
Value20.3±3.9 μM
POI NamePlk1
Cell LineHela
Cell Line IDCVCL_0030
Assay MethodWB
Reference10.1039/c9ob00080a

Description

exposure of HeLa cells to the hydrophobically tagged compound 2 for 24 h revealed a strong and dose-dependent reduction in Plk1 protein levels (apparent IC50 = 20.3 ± 3.9 μM),

TypeIC50,
Value48.2±4.9 μM
POI NamePlk1
Assay Methodfluorescence polarization assay(FP)
Reference10.1039/c9ob00080a

Description

2 was tested in competitive binding assays based on fluorescence polarization (FP) against the PBDs of Plk1, Plk2, and Plk3. 34,35 2 showed slight selectivity for the Plk1 PBD (apparent IC 50 = 48.2 ± 4.9 μM) over the Plk2 PBD (apparent IC50 = 54.8 ± 11.0 μM), and substantially higher selectivity over the Plk3 PBD (34 ± 4% inhibition at 100 μM, the highest concentration tested, Fig. 3A).

TypeIC50
Value54.8±11.0 μM
POI NamePlk2
Assay Methodfluorescence polarization assay(FP)
Reference10.1039/c9ob00080a

Description

2 was tested in competitive binding assays based on fluorescence polarization (FP) against the PBDs of Plk1, Plk2, and Plk3. 34,35 2 showed slight selectivity for the Plk1 PBD (apparent IC 50 = 48.2 ± 4.9 μM) over the Plk2 PBD (apparent IC50 = 54.8 ± 11.0 μM), and substantially higher selectivity over the Plk3 PBD (34 ± 4% inhibition at 100 μM, the highest concentration tested, Fig. 3A).

Type34 ± 4 % inhibition
Value100 μM
POI NamePlk3
Assay Methodfluorescence polarization assay(FP)
Reference10.1039/c9ob00080a

Description

2 was tested in competitive binding assays based on fluorescence polarization (FP) against the PBDs of Plk1, Plk2, and Plk3. 34,35 2 showed slight selectivity for the Plk1 PBD (apparent IC 50 = 48.2 ± 4.9 μM) over the Plk2 PBD (apparent IC50 = 54.8 ± 11.0 μM), and substantially higher selectivity over the Plk3 PBD (34 ± 4% inhibition at 100 μM, the highest concentration tested, Fig. 3A).

TypeIC50
Value9.2±0.9 μM
POI NamePlk1
Cell LineHela
Cell Line IDCVCL_0030
Assay MethodWST-1 assay
Reference10.1039/c9ob00080a

Description

Since Plk1 is required for tumor cell proliferation and survival, its degradation by the hydrophobically tagged compound should reduce cell viability. Exposure of HeLa cells to 2 for 24 h induced a dose-dependent reduction of HeLa cell viability (IC50 = 9.2 ± 0.9 μM), which is a stronger effect than was observed for 1 (IC50 = 14.0 ± 0.6 μM, Fig. 5A).

Disease Information

DiseaseICD-11Source
endocervical adenocarcinomaXH0GS9Cell Line Origin
Gonococcal keratitisLA05.1Gene-Disease Association
RhabdosarcomaXH0GA1Gene-Disease Association
Squamous Cell CarcinomaXH0945Gene-Disease Association
MedulloblastomaXH8P29Gene-Disease Association
Ovarian Cancer2C73.ZGene-Disease Association
Soft Tissue SarcomaXH4UM7Gene-Disease Association
Ataxia-telangiectasia4A01.31Gene-Disease Association